AVCTF:OTC-Avacta Group Plc (USD)

COMMON STOCK | Medical Devices | OTC

Last Closing Price

USD 1.60

Change

0.00 (0.00)%

Market Cap

N/A

Volume

3.50K

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-24 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SNNUF Smith & Nephew plc

-0.78 (-4.27%)

USD16.12B 29.10 15.49
CHEOY Cochlear Limited

-4.74 (-5.51%)

USD11.32B 47.94 29.59
MCRPF MicroPort Scientific Corporati..

N/A

USD11.28B 219.70 53.08
CHEOF Cochlear Limited

-11.00 (-6.43%)

USD11.27B 47.62 29.59
GGNDF GN Store Nord A/S

N/A

USD9.70B 30.53 2.65
GNNDY GN Store Nord A/S

+1.50 (+0.67%)

USD9.50B 30.12 2.65
MEDGF Medacta Group SA

N/A

USD3.26B 36.88 31.69
NHNKY Nihon Kohden Corporation

-0.88 (-4.76%)

USD3.00B 15.00 0.07
NHNKF Nihon Kohden Corporation

N/A

USD2.11B 24.60 -78.50
DWRKF Drägerwerk AG & Co. KGaA

N/A

USD2.00B 36.15 N/A

ETFs Containing AVCTF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.34% 48% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.34% 48% F 49% F
Trailing 12 Months  
Capital Gain -25.93% 28% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.93% 28% F 19% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 11.02% 31% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.02% 31% F 45% F
Risk Return Profile  
Volatility (Standard Deviation) 36.44% 85% B 60% D-
Risk Adjusted Return 30.24% 52% F 50% F
Market Capitalization N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.24 93% A 89% B+
Price / Cash Flow Ratio N/A N/A N/A N/A N/A
EV/EBITDA -4.60 100% A+ 92% A-
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital N/A N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.